Meeting
2020 Gastrointestinal Cancers Symposium
Prospective DPYD testing and dose adjustment in colorectal cancer patients prior to fluoropyrimidine-based chemotherapy: Experience in a regional cancer center.
Authors
Janet Shirley Graham
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Janet Shirley Graham , Jocelyn Saunders , Gregory Naylor , Christine Crearie , Wendy Campbell , Tareq Abdullah , Mary G. Dunn , Nicholas James MacLeod , Alec McDonald , Gillian McGaffin , Anne Jane McKillop , Laura Miller , Nazia Mohammed , Aqilah Othman , Liz Radford , Karen Smith , Dawn Jane Storey , Nicola Williams , Paul Westwood , Richard H. Wilson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 93)
Abstract #
93
Poster Bd #
E1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel
Poster
2021 ASCO Annual Meeting
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
First Author: Côme De Metz
Poster
2016 ASCO Annual Meeting
Hospitalizations and deaths within 60 days of fluoropyrimidine chemotherapy initiation among Medicare patients with colorectal cancer.
First Author: Gabriel Brooks
Poster
2013 ASCO Annual Meeting
Comprehensive pharmacogenetic profiling of advanced colorectal cancer.
First Author: Ayman Madi